Harvey Lalach
President, CFO, Secretary and Director
For the past 21 years, Harvey Lalach has been involved in various aspects of the securities industry. From 1986 through to 1997, he held various roles in financial institutions such as TD Bank and BMO Nesbitt Burns. For the past 10 years, Mr. Lalach has focused exclusively on the operation and administration of numerous start-up American and Canadian public companies, serving in both Director and Officer capacities. Mr. Lalach has extensive experience in the management and governance of publicly listed companies.

Alexandre Vamvakides, Ph.D.
Scientific Founder, Chief Scientific Officer, Chairman of Scientific Advisory Board
Dr. Vamvakides has spent 30 years in research, focusing on the therapeutic/ pharmacological areas of nootropes, anti-neurodegenerative (anti-Alzheimer), anti-epileptic, anti-depressive and prototype molecules. The author of 80+ published scientific papers, he has worked at the Institut National de la Sante et de la Recherche Medicale in Paris, France, University of Athens (Greece), Ciba-Geigy (Basel, Switzerland), Sanofi (Montpellier, France), and many other European research labs for the discovery and development of new concepts in the therapeutic areas of CNS, oncology and anti-inflammatory diseases.

George Kalkanis, Ph.D.
Vice President, Strategic Planning
Dr. Kalkanis has 15+ years experience in business modelling and analysis. From 1996 to present, he has been Managing Director of PROACTION LLC, providing consulting services to managerial decision makers in various sectors, primarily in banking and finance, equity markets, oil, and pharmaceuticals throughout Europe. In the pharmaceutical sector, Dr. Kalkanis has provided business forecasting and marketing analysis solutions to pharmaceutical companies, such as Novartis and Boehringer Ingelheim.